Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Authors: Loong, Herbert, Brunello, Antonella, Krieg, Andreas, Algulnik, Mark, Riedel, Richard, Okuno, Scott, Loggers, Elizabeth, Alcindor, Thierry, Ferraresi, Virginia, Serrano, César, Randall, R. Lor, Wilky, Breelyn, Ravi, Vinod, Gelderblom, Hans ^{a, *, *}, Bhadri, Vivek ^b, Stacchiotti, Silvia ^c, Bauer, Sebastian ^{d, e}, Wagner, Andrew J ^f, van de Sande, Michiel ^a, Bernthal, Nicholas M ^g, López Pousa, Antonio ^h, Razak, Albiruni Abdul ⁱ, Italiano, Antoine ^{j, k}, Ahmed, Mahbubl ^l, Le Cesne, Axel ^m, Tinoco, Gabriel ⁿ, Boye, Kjetil ^o, Martín-Broto, Javier ^p, Palmerini, Emanuela ^q, Tafuto, Salvatore ^r, Pratap, Sarah ^s, Powers, Benjamin C ^t, Reichardt, Peter ^u, Casado Herráez, Antonio ^v, Rutkowski, Piotr ^w, Tait, Christopher ^x, Zarins, Fiona ^x, Harrow, Brooke ^x, Sharma, Maitreyi G ^x, Ruiz-Soto, Rodrigo ^x, Sherman, Matthew L ^x, Blay, Jean-Yves ^y, Tap, William D ^{z, aa, *}

Source: In The Lancet 22-28 June 2024 403(10445):2709-2719

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

Authors: Gelderblom, Hans, Jones, Robin L., Blay, Jean-Yves, George, Suzanne, von Mehren, Margaret, Zalcberg, John R., Kang, Yoon-Koo, Razak, Albiruni Abdul, Trent, Jonathan, Attia, Steven, Le Cesne, Axel, Siontis, Brittany L., Goldstein, David, Boye, Kjetil, Sanchez, Cesar, Steeghs, Neeltje, Rutkowski, Piotr, Druta, Mihaela, Serrano, César, Somaiah, Neeta, Chi, Ping, Harrow, Brooke, Becker, Claus, Reichmann, William, Sherman, Matthew L., Ruiz-Soto, Rodrigo, Heinrich, Michael C., Bauer, Sebastian

Source: In European Journal of Cancer October 2023 192

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Authors: Bauer, Sebastian, Jones, Robin L., Blay, Jean-Yves, Gelderblom, Hans, George, Suzanne, Schöffski, Patrick, von Mehren, Margaret, Zalcberg, John R., Kang, Yoon-Koo, Razak, Albiruni Abdul, Trent, Jonathan, Attia, Steven, Le Cesne, Axel, Su, Ying, Meade, Julie, Wang, Tao, Sherman, Matthew L., Ruiz-Soto, Rodrigo, Heinrich, Michael C.

Source: Journal of clinical oncology. 40(34):3918-3928

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100174765350.0x000001&indx=1&recIds=ETOCvdc_100174765350.0x000001

INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations.

Authors: Heinrich, Michael C., Blay, Jean-Yves, Chi, Ping, Jones, Robin Lewis, Serrano, César, Somaiah, Neeta, Gelderblom, Hans, Zalcberg, John Raymond, Reichmann, William, Sprott, Kam, Sherman, Matthew L., Bauer, Sebastian, George, Suzanne

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, pTPS848-TPS848, 47p

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study

Authors: Zalcberg, John R., Heinrich, Michael C., George, Suzanne, Bauer, Sebastian, Schöffski, Patrick, Serrano, César, Gelderblom, Hans, Jones, Robin L., Attia, Steven, D'Amato, Gina, Chi, Ping, Reichardt, Peter, Somaiah, Neeta, Meade, Julie, Reichert, Vienna, Shi, Kelvin, Sherman, Matthew L., Ruiz‐Soto, Rodrigo, Mehren, Margaret, Blay, Jean‐Yves

Source: Oncologist. 26(11):e2053-e2060

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100132896174.0x000001&indx=1&recIds=ETOCvdc_100132896174.0x000001

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.

Authors: George, Suzanne, Blay, Jean-Yves, Chi, Ping, Jones, Robin L, Serrano, César, Somaiah, Neeta, Gelderblom, Hans, Zalcberg, John R, Reichmann, William, Sprott, Kam, Cox, Paulina, Sherman, Matthew L, Ruiz-Soto, Rodrigo, Heinrich, Michael C, Bauer, Sebastian

Source: Future Oncology; 2024, Vol. 20 Issue 27, p1973-1982, 10p

Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification

Authors: Coyne, Daniel W., Singh, Hem N., Smith, William T., Giuseppi, Ana Carolina, Connarn, Jamie N., Sherman, Matthew L., Dellanna, Frank, Malluche, Hartmut H., Hruska, Keith A.

Source: In Kidney International Reports November 2019 4(11):1585-1597

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia

Authors: Piga, Antonio ^*, Perrotta, Silverio, Gamberini, Maria Rita, Voskaridou, Ersi, Melpignano, Angela, Filosa, Aldo, Caruso, Vincenzo, Pietrangelo, Antonello, Longo, Filomena, Tartaglione, Immacolata, Borgna-Pignatti, Caterina, Zhang, Xiaosha, Laadem, Abderrahmane, Sherman, Matthew L., Attie, Kenneth M.

Source: In Blood 21 March 2019 133(12):1279-1289

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

Authors: Voss, Martin H., Bhatt, Rupal S., Vogelzang, Nicholas J., Fishman, Mayer, Alter, Robert S., Rini, Brian I., Beck, J. Thaddeus, Joshi, Monika, Hauke, Ralph, Atkins, Michael B., Burgess, Earle, Logan, Theodore F., Shaffer, David, Parikh, Rahul, Moazzam, Nauman, Zhang, Xiaosha, Glasser, Chad, Sherman, Matthew L., Plimack, Elizabeth R.

Source: Cancer. 125(14):2400-2408

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100084329548.0x000001&indx=1&recIds=ETOCvdc_100084329548.0x000001

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Authors: Platzbecker, Uwe, Germing, Ulrich, Götze, Katharina S, Kiewe, Philipp, Mayer, Karin, Chromik, Jörg, Radsak, Markus, Wolff, Thomas, Zhang, Xiaosha, Laadem, Abderrahmane, Sherman, Matthew L, Attie, Kenneth M, Giagounidis, Aristoteles

Source: In The Lancet Oncology October 2017 18(10):1338-1347

Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Authors: Gelderblom, Hans, Bhadri, Vivek, Stacchiotti, Silvia, Bauer, Sebastian, Wagner, Andrew J, van de Sande, Michiel, Bernthal, Nicholas M, López Pousa, Antonio, Razak, Albiruni Abdul, Italiano, Antoine, Ahmed, Mahbubl, Le Cesne, Axel, Tinoco, Gabriel, Boye, Kjetil, Martín-Broto, Javier, Palmerini, Emanuela, Tafuto, Salvatore, Pratap, Sarah, Powers, Benjamin C, Reichardt, Peter, Casado Herráez, Antonio, Rutkowski, Piotr, Tait, Christopher, Zarins, Fiona, Harrow, Brooke, Sharma, Maitreyi G, Ruiz-Soto, Rodrigo, Sherman, Matthew L, Blay, Jean-Yves, Tap, William D, Loong, Herbert, Brunello, Antonella, Krieg, Andreas, Algulnik, Mark, Riedel, Richard, Okuno, Scott, Loggers, Elizabeth, Alcindor, Thierry, Ferraresi, Virginia, Serrano, César, Randall, R. Lor, Wilky, Breelyn, Ravi, Vinod

Source: The Lancet; June 2024, Vol. 403 Issue: 10445 p2709-2719, 11p

The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.

Authors: Tap, William D, Sharma, Maitreyi G, Vallee, Marc, Smith, Bryan D, Sherman, Matthew L, Ruiz-Soto, Rodrigo, de Sande, Michiel van, Randall, R Lor, Bernthal, Nicholas M, Gelderblom, Hans

Source: Future Oncology; Mar2024, Vol. 20 Issue 10, p593-601, 9p

INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations.

Authors: Zalcberg, John Raymond, Blay, Jean-Yves, Chi, Ping, Jones, Robin Lewis, Serrano, Cesar, Somaiah, Neeta, Reichmann, William, Sprott, Kam, Cox, Paulina, Sherman, Matthew L., Ruiz-Soto, Rodrigo, Heinrich, Michael C., Bauer, Sebastian, George, Suzanne

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, pTPS767-TPS767, 42p

Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.

Authors: Zalcberg, John Raymond, Jones, Robin Lewis, Blay, Jean-Yves, George, Suzanne, Gelderblom, Hans, Schöffski, Patrick, von Mehren, Margaret, Kang, Yoon-Koo, Abdul Razak, Albiruni Ryan, Trent, Jonathan C., Attia, Steven, Le Cesne, Axel, Davis, Erika, Achour, Haroun, Sherman, Matthew L., Ruiz-Soto, Rodrigo, Bauer, Sebastian, Heinrich, Michael C.

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p748-748, 42p

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Authors: Heinrich, Michael C., Jones, Robin L., George, Suzanne, Gelderblom, Hans, Schöffski, Patrick, von Mehren, Margaret, Zalcberg, John R., Kang, Yoon-Koo, Razak, Albiruni Abdul, Trent, Jonathan, Attia, Steven, Le Cesne, Axel, Siontis, Brittany L., Goldstein, David, Boye, Kjetil, Sanchez, Cesar, Steeghs, Neeltje, Rutkowski, Piotr, Druta, Mihaela, Serrano, César, Somaiah, Neeta, Chi, Ping, Reichmann, William, Sprott, Kam, Achour, Haroun, Sherman, Matthew L., Ruiz-Soto, Rodrigo, Blay, Jean-Yves, Bauer, Sebastian

Source: Nature Medicine; February 2024, Vol. 30 Issue: 2 p498-506, 9p

A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma

Authors: Abou‐Alfa, Ghassan K., Miksad, Rebecca A., Tejani, Mohamedtaki A., Williamson, Stephen, Gutierrez, Martin E., Olowokure, Olugbenga O., Sharma, Manish R., El Dika, Imane, Sherman, Matthew L., Pandya, Shuchi S.

Source: Oncologist. 24(2):161-e70

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100082765052.0x000001&indx=1&recIds=ETOCvdc_100082765052.0x000001

Ionizing Radiation Regulates Expression of the c-jun Protooncogene

Authors: Sherman, Matthew L., Datta, Rakesh, Hallahan, Dennis E., Weichselbaum, Ralph R., Kufe, Donald W.

Source: Proceedings of the National Academy of Sciences of the United States of America, 1990 Aug 01. 87(15), 5663-5666.

Access URL: https://www.jstor.org/stable/2354983

Protein Kinase C Mediates X-Ray Inducibility of Nuclear Signal Transducers EGR1 and JUN

Authors: Hallahan, Dennis E., Sukhatme, Vikas P., Sherman, Matthew L., Virudachalam, Subbulakshmi, Kufe, Donald, Weichselbaum, Ralph R.

Source: Proceedings of the National Academy of Sciences of the United States of America, 1991 Mar . 88(6), 2156-2160.

Access URL: https://www.jstor.org/stable/2356339

ANTAGONISTS OF ACTRIIB AND USES FOR INCREASING RED BLOOD CELL LEVELS

ACTIVIN-ACTRIIA ANTAGONISTS FOR INHIBITING GERM CELL MATURATION